SCHEMBL20606396

SCHEMBL20606396

CC(=O)NS(=O)(=O)N1CC[CH]CC1

nearest known ligand 0.36

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.36
FKBP1A P62942 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
DHFR P00374 1/20 0.32
TSHR P16473 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.31
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19630970 0.81 GAA (0.45) GAAFKBP1AMEN1KMT2ATSHR
SCHEMBL26873959 0.81 GAA (0.41) GAAFKBP1AMEN1KMT2ATSHR
SCHEMBL19631003 0.79 GAA (0.47) GAAFKBP1AMEN1KMT2ATSHR
SCHEMBL13249203 0.79 GAA (0.47) GAAFKBP1AMEN1KMT2ATSHR
SCHEMBL13249204 0.78 APEX1 (0.36) GAAKMT2A
SCHEMBL19631000 0.74 PIK3C3 (0.40) GAAPOLB
SCHEMBL1376664 0.74 FKBP1A (0.32) FKBP1A
SCHEMBL9565844 0.68 HSD11B1 (0.51) GAAMEN1KMT2ATSHRSMN1; SMN2
SCHEMBL196906 0.66 LMNA (0.42) MEN1KMT2ATSHRSMN1; SMN2
SCHEMBL1705467 0.66 GAA (0.46) GAAFKBP1AMEN1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109153665-B Novel 2-substituted indazoles, method for the production thereof, pharmaceutical preparations containing the same and use thereof for producing medicaments 拜耳医药股份有限公司 2021-10-15 CN claimed
EP-3423446-B1 NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS Bayer Pharma AG (DE) 2020-09-16 EP claimed
US-10435396-B2 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs BAYER PHARMA AKTIEGESELLSCHAFT (DE) 2019-10-08 US claimed
US-20190071432-A1 NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-03-07 US claimed
EP-3423446-A1 NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS Bayer Pharma Aktiengesellschaft (DE) 2019-01-09 EP claimed
CN-109153665-A Novel 2-substituted indazoles, method for the production thereof, pharmaceutical preparations containing the same and use thereof for producing medicaments 拜耳医药股份有限公司 2019-01-04 CN claimed
CN-109153665-B Novel 2-substituted indazoles, method for the production thereof, pharmaceutical preparations containing the same and use thereof for producing medicaments 拜耳医药股份有限公司 2021-10-15 CN disclosed
EP-3423446-B1 NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS Bayer Pharma AG (DE) 2020-09-16 EP disclosed
US-10435396-B2 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs BAYER PHARMA AKTIEGESELLSCHAFT (DE) 2019-10-08 US disclosed
US-20190071432-A1 NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-03-07 US disclosed
EP-3423446-A1 NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS Bayer Pharma Aktiengesellschaft (DE) 2019-01-09 EP disclosed
CN-109153665-A Novel 2-substituted indazoles, method for the production thereof, pharmaceutical preparations containing the same and use thereof for producing medicaments 拜耳医药股份有限公司 2019-01-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10435396-B2 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs CYP11B2, CYP19A1, CYP11B1 GAA 2934/4885FKBP1A 725/4885MEN1 1730/4885
US-20190071432-A1 NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS CYP11B2, CYP19A1, CYP11B1 GAA 2908/4885FKBP1A 707/4885MEN1 1644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.